Pregnant & Breastfeeding Women Who Get the COVID-19 Vaccine Are Protecting Their Infants, Research Suggests
Becky Cummings had multiple reasons to get vaccinated against COVID-19 while tending to her firstborn, Clark, who arrived in September 2020 at 27 weeks.
The 29-year-old intensive care unit nurse in Greensboro, North Carolina, had witnessed the devastation day in and day out as the virus took its toll on the young and old. But when she was offered the vaccine, she hesitated, skeptical of its rapid emergency use authorization.
Exclusion of pregnant and lactating mothers from clinical trials fueled her concerns. Ultimately, though, she concluded the benefits of vaccination outweighed the risks of contracting the potentially deadly virus.
"Long story short," Cummings says, in December "I got vaccinated to protect myself, my family, my patients, and the general public."
At the time, Cummings remained on the fence about breastfeeding, citing a lack of evidence to support its safety after vaccination, so she pumped and stashed breast milk in the freezer. Her son is adjusting to life as a preemie, requiring mother's milk to be thickened with formula, but she's becoming comfortable with the idea of breastfeeding as more research suggests it's safe.
"If I could pop him on the boob," she says, "I would do it in a heartbeat."
Now, a study recently published in the Journal of the American Medical Association found "robust secretion" of specific antibodies in the breast milk of mothers who received a COVID-19 vaccine, indicating a potentially protective effect against infection in their infants.
The presence of antibodies in the breast milk, detectable as early as two weeks after vaccination, lasted for six weeks after the second dose of the Pfizer-BioNTech vaccine.
"We believe antibody secretion into breast milk will persist for much longer than six weeks, but we first wanted to prove any secretion at all after vaccination," says Ilan Youngster, the study's corresponding author and head of pediatric infectious diseases at Shamir Medical Center in Zerifin, Israel.
That's why the research team performed a preliminary analysis at six weeks. "We are still collecting samples from participants and hope to soon be able to comment about the duration of secretion."
As with other respiratory illnesses, such as influenza and pertussis, secretion of antibodies in breast milk confers protection from infection in infants. The researchers expect a similar immune response from the COVID-19 vaccine and are expecting the findings to spur an increase in vaccine acceptance among pregnant and lactating women.
A COVID-19 outbreak struck three families the research team followed in the study, resulting in at least one non-breastfed sibling developing symptomatic infection; however, none of the breastfed babies became ill. "This is obviously not empirical proof," Youngster acknowledges, "but still a nice anecdote."
Leaps.org inquired whether infants who derive antibodies only through breast milk are likely to have a lower immunity than infants whose mothers were vaccinated while they were in utero. In other words, is maternal transmission of antibodies stronger during pregnancy than during breastfeeding, or about the same?
"This is a different kind of transmission," Youngster explains. "When a woman is infected or vaccinated during pregnancy, some antibodies will be transferred through the placenta to the baby's bloodstream and be present for several months." But in the nursing mother, that protection occurs through local action. "We always recommend breastfeeding whenever possible, and, in this case, it might have added benefits."
A study published online in March found COVID-19 vaccination provided pregnant and lactating women with robust immune responses comparable to those experienced by their nonpregnant counterparts. The study, appearing in the American Journal of Obstetrics and Gynecology, documented the presence of vaccine-generated antibodies in umbilical cord blood and breast milk after mothers had been vaccinated.
Natali Aziz, a maternal-fetal medicine specialist at Stanford University School of Medicine, notes that it's too early to draw firm conclusions about the reduction in COVID-19 infection rates among newborns of vaccinated mothers. Citing the two aforementioned research studies, she says it's biologically plausible that antibodies passed through the placenta and breast milk impart protective benefits. While thousands of pregnant and lactating women have been vaccinated against COVID-19, without incurring adverse outcomes, many are still wondering whether it's safe to breastfeed afterward.
It's important to bear in mind that pregnant women may develop more severe COVID-19 complications, which could lead to intubation or admittance to the intensive care unit. "We, in our practice, are supporting pregnant and breastfeeding patients to be vaccinated," says Aziz, who is also director of perinatal infectious diseases at Stanford Children's Health, which has been vaccinating new mothers and other hospitalized patients at discharge since late April.
Earlier in April, Huntington Hospital in Long Island, New York, began offering the COVID-19 vaccine to women after they gave birth. The hospital chose the one-shot Johnson & Johnson vaccine for postpartum patients, so they wouldn't need to return for a second shot while acclimating to life with a newborn, says Mitchell Kramer, chairman of obstetrics and gynecology.
The hospital suspended the program when the Food and Drug Administration and the Centers for Disease Control and Prevention paused use of the J&J vaccine starting April 13, while investigating several reports of dangerous blood clots and low platelet counts among more than 7 million people in the United States who had received that vaccine.
In lifting the pause April 23, the agencies announced the vaccine's fact sheets will bear a warning of the heightened risk for a rare but serious blood clot disorder among women under age 50. As a result, Kramer says, "we will likely not be using the J&J vaccine for our postpartum population."
So, would it make sense to vaccinate infants when one for them eventually becomes available, not just their mothers? "In general, most of the time, infants do not have as good of an immune response to vaccines," says Jonathan Temte, associate dean for public health and community engagement at the University of Wisconsin School of Medicine and Public Health in Madison.
"Many of our vaccines are held until children are six months of age. For example, the influenza vaccine starts at age six months, the measles vaccine typically starts one year of age, as do rubella and mumps. Immune response is typically not very good for viral illnesses in young infants under the age of six months."
So far, the FDA has granted emergency use authorization of the Pfizer-BioNTech vaccine for children as young as 16 years old. The agency is considering data from Pfizer to lower that age limit to 12. Studies are also underway in children under age 12. Meanwhile, data from Moderna on 12-to 17-year-olds and from Pfizer on 12- to 15-year-olds have not been made public. (Pfizer announced at the end of March that its vaccine is 100 percent effective in preventing COVID-19 in the latter age group, and FDA authorization for this population is expected soon.)
"There will be step-wise progression to younger children, with infants and toddlers being the last ones tested," says James Campbell, a pediatric infectious diseases physician and head of maternal and child clinical studies at the University of Maryland School of Medicine Center for Vaccine Development.
"Once the data are analyzed for safety, tolerability, optimal dose and regimen, and immune responses," he adds, "they could be authorized and recommended and made available to American children." The data on younger children are not expected until the end of this year, with regulatory authorization possible in early 2022.
For now, Vonnie Cesar, a family nurse practitioner in Smyrna, Georgia, is aiming to persuade expectant and new mothers to get vaccinated. She has observed that patients in metro Atlanta seem more inclined than their rural counterparts.
To quell some of their skepticism and fears, Cesar, who also teaches nursing students, conceived a visual way to demonstrate the novel mechanism behind the COVID-19 vaccine technology. Holding a palm-size physical therapy ball outfitted with clear-colored push pins, she simulates the spiked protein of the coronavirus. Slime slathered at the gaps permeates areas around the spikes—a process similar to how our antibodies build immunity to the virus.
These conversations often lead hesitant patients to discuss vaccination with their husbands or partners. "The majority of people I'm speaking with," she says, "are coming to the conclusion that this is the right thing for me, this is the common good, and they want to make sure that they're here for their children."
CORRECTION: An earlier version of this article mistakenly stated that the COVID-19 vaccines were granted emergency "approval." They have been granted emergency use authorization, not full FDA approval. We regret the error.
Is Alzheimer's Research On the Wrong Track?
"The graveyard of hope." That's what experts call the quest for effective Alzheimer's treatments, a two-decade effort that has been marked by one costly and high-profile failure after another. Nearly all of the drugs tested target one of the key hallmarks of Alzheimer's disease: amyloid plaques, the barnacle-like proteins long considered the culprits behind the memory-robbing ravages of the disease. Yet all the anti-amyloid drugs have flopped miserably, prompting some scientists to believe we've fingered the wrong villain.
"We're flogging a dead horse," says Peter Davies, PhD, an Alzheimer's researcher at the Feinstein Institute for Medical Research in New York. "The fact that no one's gotten better suggests that you have the wrong mechanism."
If the naysayers are right, how could a scientific juggernaut of this magnitude—involving hundreds of scientists in academia and industry at a cost of tens of billions of dollars--be so far off the mark? There are no easy answers, but some experts believe this calls into question how research is conducted and blame part of the failure on the insular culture of the scientific aristocracy at leading academic institutions.
"The field began to be dominated by narrow views."
"The field began to be dominated by narrow views," says George Perry, PhD, an Alzheimer's researcher and dean of the College of Sciences at the University of Texas in San Antonio. "The people pushing this were incredibly articulate, powerful and smart. They'd go to scientific meetings and all hang around with each other and they'd self-reinforce."
In fairness, there was solid science driving this. Post-mortem analyses of Alzheimer's patients found their brains were riddled with amyloid plaques. People with a strong family history of Alzheimer's had genetic mutations in the genes that encode for the production of amyloids. And in animal studies, scientists found that if amyloids were inserted into the brains of transgenic mice, they exhibited signs of memory loss. Remove the amyloids and they suddenly got better. This body of research helped launch the Amyloid Cascade Hypothesis of the disease in 1992—which has driven research ever since.
Scientists believed that the increase in the production of these renegade proteins, which form sticky plaques and collect outside of the nerve cells in the brain, triggers a series of events that interfere with the signaling system between synapses. This seems to prevent cells from relaying messages or talking to each other, causing memory loss, confusion and increasing difficulties doing the normal tasks of life. The path forward seemed clear: stop amyloid production and prevent disease progression. "We were going after the obvious abnormality," says Dr. David Knopman, a neurologist and Alzheimer's researcher at the Mayo Clinic in Rochester, Minnesota.
"Why wouldn't you do that?" Why ideed.
In hindsight, though, there was no real smoking gun—no one ever showed precisely how the production of amyloids instigates the destruction of vital brain circuits.
"Amyloids are clearly important," says Perry, "but they have not proven to be necessary and sufficient for the development of this disease."
Ironically, there have been hints all along that amyloids may not be toxic bad boys.
A handful of studies revealed that amyloid proteins are produced in healthy brains to protect synapses. Research on animal models that mimic diseases suggest that certain forms of amyloids can ease damage from strokes, traumatic brain injuries and even heart attacks. In a 2013 study, to cite just one example, a Stanford University team injected synthetic amyloids into paralyzed mice with an inflammatory disorder similar to multiple sclerosis. Instead of worsening their symptoms—which is what the researchers expected to happen--the mice could suddenly walk again. Remove the amyloids, and they became paralyzed once more.
Still other studies suggest amyloids may actually function as molecular guardians dispatched to silence inflammation and mop up errant cells after an injury as part of the body's waste management system. "The presence of amyloids is a protective response to something going wrong, a threat," says Dr. Dale Bredesen, a UCLA neurologist. "But the problem arises when the threats are chronic, multiple, unrelenting and intense. The defenses the brain mounts are also intense and these protective mechanisms cross the line into causing harm, and killing the very synapses and brain cells the amyloid was called up to protect."
So how did research get derailed?
In a way, we're victims of our own success, critics say.
Early medical triumphs in the heady post-World War II era, like the polio vaccine that eradicated the crippling childhood killer, or antibiotics, reinforced the magic bullet idea of curing disease--find a target and then hit it relentlessly. That's why when scientists made the link between amyloids and disease progression, Big Pharma jumped on the bandwagon in hopes of inventing a trillion-dollar drug. This approach is fine when you have an acute illness, like an infectious disease that's caused by one agent, but not for something as complicated as Alzheimer's.
The other piece of the problem is the dwindling federal dollars for basic research. Maverick scientists find it difficult to secure funding, which means that other possible targets or approaches remained relatively unexplored—and drug companies are understandably reluctant to sponsor fishing expeditions with little guarantee of a payoff. "Very influential people were driving this hypothesis," says Davies, and with careers on the line, "there was not enough objectivity or skepticism about that hypothesis."
Still, no one is disputing the importance of anti-amyloid drugs—and ongoing clinical trials, like the DIAN and A4 studies, are intervening earlier in patients who are at a high risk of developing Alzheimer's, but before they're symptomatic. "The only way to know if this is really a dead end is if you take it as far as it can go," says Knopman. "I believe the A4 study is the proper way to test the amyloid hypothesis."
But according to some experts, the latest thinking is that Alzheimer's is triggered by a range of factors, including genetics, poor diet, stress and lack of exercise.
"Alzheimer's is like other chronic age-related diseases and is multi-factorial," says Perry. "Modulating amyloids may have value but other avenues need to be explored."
Just Say No to Editing Human Embryos for Reproduction
BIG QUESTION OF THE MONTH: Should we use CRISPR, the new technique that enables precise DNA editing, to change the genes of human embryos to eradicate disease – or even to enhance desirable traits? LeapsMag invited three leading experts to weigh in.
Over the last few decades, the international community has issued several bioethical guidelines and legally binding documents, ranging from UN Declarations to regional charters to national legislation, about editing the human germline--the DNA that is passed down to future generations. There was a broad consensus that modifications should be prohibited. But now that CRISPR-cas9 and related methods of gene editing are taking the world by storm, that stance is softening--and so far, no thorough public discussion has emerged.
There is broad agreement in the scientific and ethics community that germline gene editing must not be clinically applied unless safety concerns are resolved. Predicting that safety issues will indeed be minimized, the National Academy of Sciences issued a report this past February that sets up several procedural norms. These may serve as guidelines for future implementation of human embryo editing, among them that there are no "reasonable alternatives," a condition that is left deliberately vague.
I regard the conditional embrace of germline gene editing as a grave mistake: It is a dramatic break with the previous idea of a ban, departing also from the moratorium that the UNESCO International Bioethics Committee had recommended in 2015. But in a startling move, the Academy already set the next post, recommending "that genome editing for purposes other than treatment or prevention of disease and disability should not proceed at this time" (my emphasis). It recommended public discussions, but without spelling out its own role in facilitating them.
"The international community should explicitly ban embryo gene editing as a method of human reproduction."
To proceed ethically, I argue that the international community, through the United Nations and in line with the ban on human reproductive cloning, should explicitly ban embryo gene editing as a method of human reproduction. Together with guidelines adjusted for non-reproductive and non-human applications, a prohibition would ensure two important results: First, that non-reproductive human embryo research could be pursued in a responsible way in those countries that allow for it, and second, that individual scientists, public research institutes, and private companies would know the moral limit of possible research.
Basic human embryo research is required, scientists argue, to better understand genetic diseases and early human development. I do not question this, and I am convinced that existing guidelines can be adjusted to meet the moral requirements in this area. Millions of people may benefit from different non-reproductive pathways of gene editing. Germline gene editing, in contrast, does not offer any resolutions to global or local health problems – and that alone raises many concerns about the current state of scientific research.
I support a ban because germline gene editing for reproductive purposes concerns more than safety. The genetic modification of a human being is irreversible and unpredictable in its epigenetic, personal, and social effects. It concerns the rights of children; it exposes persons with disabilities to social stigmatization; it contradicts the global justice agenda with respect to healthcare; and it infringes upon the rights to freedom and well-being of future persons.
"Reproductive germline gene editing directly violates the rights of individual future person."
Apart from questions of justice, reproductive germline gene editing may well increase the stigmatization of persons with disabilities. I want to emphasize here, however, that it directly violates the rights of individual future persons, namely a future child's right to genetic integrity, to freedom, and potentially to well-being, all guaranteed in different UN Declarations of Human Rights. For all these reasons, it is an unacceptable path forward.
The way the discussion has been framed so far is very different from my perspective that situates germline gene editing in the broader framework of human rights and responsibilities. In short, many others never questioned the goal but instead focused on the unintentional side-effects of an otherwise beneficial technique for human reproduction. Some scientists see germline gene editing as an alternative to embryo selection via Preimplantation Genetic Diagnosis (PGD), a procedure in which multiple embryos are tested to find out which ones carry disease-causing mutations. Others see it as the first step to human enhancement.
Some physicians argue that in the field of assisted reproduction, not every couple is comfortable with embryo selection via PGD, because potentially, unchosen embryos are discarded. Germline gene editing offers them an alternative. It is rarely mentioned, however, that germline gene editing would most likely still require PGD as a control of the procedure (though without the purpose of selection), and that prenatal genetic diagnosis would also be highly recommended. In other words, germline gene editing would not replace existing protocols but rather change their purpose, and it would also not necessarily reduce the number of embryos needed for assisted reproduction.
In some (rare) cases, PGD is not an option, because in the couples' condition, all embryos will be affected. One current option to avoid transmitting genetic traits is to use a donor sperm or egg, though the resulting child would not be genetically related to one parent. If these parents had an obligation, as some proponents argue, to secure the health of their offspring (an argument that I do not follow), then procreation with sperm or egg donation would even be morally required, as this is the safest procedure to erase a given genetic trait.
There are no therapeutic scenarios that exclusively require reproductive gene editing even if one accepts the right to reproductive autonomy. The fact is that couples who rightly wish to secure and protect the health of their future children can be offered medical alternatives in all cases. However, this requires considering sperm or egg donation as the safest and most reasonable option – the condition the NAS Report has set.
Scientists in favor of germline gene editing argue against this: the desire for genetic kinship, they say, is a legitimate expression of a couple's reproductive freedom, and germline gene editing offers them an alternative to have a healthy child. In the future, proponents say, these (very few) couples who wish for genetically related offspring will be faced with the dilemma of either accepting the transmission of a genetic health risk to their children or weighing the benefits and risks of gene editing.
But here is a blind spot in the whole discussion.
Many scientists and some bioethicists think that reproductive freedom includes the right to a genetically related child. But even if we were to presuppose such a right, it is not absolute in the context of assisted reproduction. Although sperm or egg donation may be undesirable for some couples, the moral question of responsibility does not disappear with their reproductive rights. At a minimum, the future child's rights must be considered, and these rights go further than their health rights.
It is puzzling that in claiming their own reproductive freedom, couples would need to ignore their children's and possibly grandchildren's future freedom – including the constraints resulting from being monitored over the course of their lives and the indirect constraints of the children's own right to reproductive freedom. From a medical standpoint, it would be highly recommended for them, too, to have children through assisted reproduction. This distinguishes germline gene editing from any other procedure of assisted reproduction: we need the data from the second and third generations to see whether the method is safe and efficacious. Whose reproductive freedom should count, the parents' or the future children's?
But for now, the question of parental rights may well divert the discussion from the question of responsible gene editing research; its conditions and structures require urgent evaluation and adjustment to guide international research groups. I am concerned that we are in the process of developing a new technology that has tremendous potential and ramifications – but without having considered the ethical framework for a responsible path forward.
Editor's Note: Check out the viewpoints expressing enthusiastic support and mild curiosity.